

#39386

DATE: JULY 25, 2016

SUBJECT: EMERGENT BIOSOLUTIONS INC. - DISTRIBUTION OPTION SYMBOL: EBS NEW SYMBOL: EBS1 DATE: 8/1/16

CONTRACT ADJUSTMENT - OPTIONS

- EFFECTIVE DATE: August 1, 2016
- OPTION SYMBOL: EBS changes to EBS1
- STRIKE PRICES: No Change

NUMBER OF CONTRACTS:

No Change

MULTIPLIER:

100 (e.g., a premium of 1.50 yields \$150; a strike of 30 yields \$3,000)

NEW DELIVERABLE PER CONTRACT

- 1) 100 Emergent BioSolutions Inc. (EBS) Common Shares
- 2) 50 (New) Aptevo Therapeutics Inc. (APVO) Common Shares

SETTLEMENT

ALLOCATION: EBS: 90% APVO: 10%

CUSIPS: EBS: 29089Q105 APVO: 03835L108

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

PRICING

The underlying price for EBS1 will be determined as follows:

EBS1 = EBS + 0.50 (APVO)

BACKGROUND

Emergent BioSolutions Inc. (EBS) has announced a distribution of (New) Aptevo Therapeutics Inc. (APVO) Common Shares. The distribution ratio is 0.50 of an APVO Common Share for each EBS Common Share held. The record date is July 22, 2016; the payable date is August 1, 2016. The New York Stock Exchange (NYSE) has set August 1, 2016 as the ex-distribution date for this distribution.

Aptevo Therapeutics Inc. Common Shares began trading on a when issued basis on July 20, 2016, on the NASDAQ Stock Market under the trading symbol "APVOV".

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email <u>investorservices@theocc.com</u>. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email <u>memberservices@theocc.com</u>.